30/05/2026
Postpartum depression is periodically dismissed by non-specialists as a cultural invention, an excuse for laziness, or a reflection of weak character. These characterizations are not benign: they delay treatment, increase suffering, and expose infants to the documented harms of disrupted maternal bonding. When subjected to systematic scrutiny — historical, neurobiological, epidemiological, and comparative — the claim dissolves entirely. PPD is a well-documented psychiatric condition, with roots traceable to antiquity and several strongly supported neurobiological mechanisms, although its pathophysiology is not yet fully understood.
The historical record alone is enough to embarrass the "modern invention" thesis. Hippocrates, writing around 400 BCE, documented a case in the Epidemics of a woman who, within one week of delivering twins, developed severe insomnia and restlessness — what he called "postpartum delirium." His theoretical explanation was wrong (he believed that suppressed uterine discharge migrated to the brain), but the clinical observation was real. Soranus of Ephesus, writing in the first century CE, described women who became sad, irritable, and potentially dangerous to their newborns after childbirth — language that maps closely onto modern descriptions of postpartum psychosis and depression. Scholars such as Freeman, Bogarad, and Sholomskas have rightly cautioned that some of these ancient cases may have represented puerperal fever delirium or postpartum psychosis rather than depression as currently defined, and this distinction matters diagnostically. The historical evidence is therefore best understood as consistent with, rather than proof of, the modern construct — but it is evidence nonetheless.
The record does not stop in antiquity. In the early fifteenth century, Margery Kempe — whose dictated autobiography is considered the first in the English language — described hallucinations, self-harm, and suicidal ideation following childbirth, experiences she attributed to demonic influence. Trotula of Salerno, the eleventh-century physician of the Salernitan school, wrote about women experiencing grief and distress after delivery in terms that later historians have read as early descriptions of puerperal mood disorders. In the Islamic tradition, Ibn Sina described melancholia and depressive states in considerable clinical detail in The Canon of Medicine, though it must be noted that evidence for a specific diagnostic category equivalent to modern postpartum depression in Islamic medicine remains limited — his descriptions concern depressive illness broadly, not the postpartum period specifically. By the sixteenth century, the Swiss physician Felix Plater was documenting agitation and delirium in women shortly after giving birth. And in 1858, the French psychiatrist Louis-Victor Marcé published a systematic study of 310 pregnant and postpartum women, reporting that 58% of those who developed mental illness did so in the puerperal period — a pattern he argued was clinically distinct from ordinary melancholia, and which led him to propose a separate diagnostic category. The international Marcé Society for Perinatal Mental Health carries his name to this day.
Modern medicine has formalized what these earlier observers could only describe. The DSM-5-TR classifies PPD as Major Depressive Disorder with Peripartum Onset, defined as beginning during pregnancy or within four weeks of delivery, though clinicians routinely apply the diagnosis through the first postpartum year to reflect real-world symptom timing. The ICD-11 similarly recognizes puerperal mental disorders as a distinct clinical category. One distinction that is frequently lost in popular discourse is the difference between PPD and the so-called "baby blues" — a transient, self-limiting emotional lability affecting up to 85% of women in the first two weeks postpartum, which resolves without treatment. PPD is categorically different: it persists, it meets full diagnostic criteria for major depressive disorder, and it requires clinical attention.
The biological substrate of PPD is now understood in considerable, though not complete, detail. During pregnancy, estrogen and progesterone rise to extraordinary levels — estrogen at term may be a hundred times higher than its non-pregnant baseline. After delivery, both hormones collapse precipitously. This rapid hormonal withdrawal is considered a major contributing factor in PPD, though it does not fully explain all cases: most women experience the same withdrawal without developing depression, which means individual biological susceptibility, genetic predisposition, and psychosocial context are also necessary parts of the picture. The more precisely characterized mechanism involves allopregnanolone, a neurosteroid derived from progesterone that acts as a potent positive modulator of GABA-A receptors — the brain's principal inhibitory receptors. During pregnancy, allopregnanolone levels rise in parallel with progesterone, producing anxiolytic and sedative effects. After delivery, they fall sharply. This neurosteroid withdrawal is among the leading mechanistic explanations currently supported by evidence, disrupting the tonic inhibitory control of limbic circuits and contributing to the emotional dysregulation, anxiety, and low mood that characterize PPD. The clinical relevance of this pathway is not merely theoretical: in 2019, the FDA approved brexanolone — a synthetic form of allopregnanolone administered intravenously — specifically for PPD, and in 2023 approved zuranolone, the first oral medication in the same class. Both drugs demonstrated significant clinical benefit in randomized controlled trials, providing direct pharmacological evidence that neurosteroid signaling is meaningfully involved in the condition's pathophysiology. Alongside these hormonal changes, the hypothalamic-pituitary-adrenal axis — the body's central stress-response system — undergoes significant postpartum reorganization, and women with PPD consistently demonstrate elevated basal cortisol, blunted stress reactivity, and impaired feedback inhibition compared to non-depressed postpartum women. Neuroimaging studies have additionally identified structural and functional differences in the amygdala, prefrontal cortex, hippocampus, and striatum in women with PPD — findings that suggest neurobiological differences associated with the condition, though larger replication studies are still needed. Inflammatory biomarker profiles, including elevated C-reactive protein and fibrinogen, have also been associated with PPD in recent cross-sectional research, consistent with growing evidence that immune dysregulation contributes to depressive disorders more broadly.
The scale of the condition globally makes the "cultural invention" thesis impossible to sustain. A meta-analysis of 565 studies drawn from 80 countries — published in Translational Psychiatry in 2021 — found a global pooled prevalence of 17.22%. A 2023 meta-analysis of 412 studies across 46 countries placed the figure at 19.18%. The World Health Organization estimates that between 10 and 20% of postpartum women are affected worldwide; current estimates suggest roughly 174 million women globally carry this burden. Rates vary substantially across countries — from under 5% in parts of Scandinavia to over 40% in Southern Africa and Afghanistan — and this variation is itself informative. A landmark meta-regression of 291 studies across 56 countries found that income inequality, maternal mortality rates, infant mortality rates, and long working hours together explained 73% of the cross-national variation in PPD prevalence. This pattern is exactly what one would expect from a condition with a real biological substrate that is amplified or buffered by social and material conditions — not from something invented for cultural convenience.
The claim that PPD reflects laziness or weak character fails on every level at which it can be evaluated. The fatigue, low motivation, and withdrawal it produces are symptoms of neurochemical dysfunction, not personality features — calling them laziness is equivalent to calling jaundice a fashion choice. PPD is associated with measurable biological abnormalities that cannot be willfully produced or suppressed: no one chooses their allopregnanolone level. It affects women across every socioeconomic class, culture, and character type, including those who are by every other measure disciplined, high-achieving, and resilient. And its response to receptor-level pharmacotherapy — treatments that work by correcting a neuroendocrine deficit, not by motivating anyone — makes a volitional explanation biologically incoherent. It is also worth noting that depressive symptoms occur in approximately 8–10% of new fathers in the postpartum period, peaking around three to six months after birth. The mechanisms differ from those in mothers — paternal postpartum depression is more closely linked to sleep deprivation, social isolation, partner depression, and changes in testosterone and prolactin — and the two conditions should not be treated as equivalent. But the occurrence of significant postpartum depression in fathers further undermines the idea that the condition is a feminine moral failure.
PPD does not stand alone as a case of depression following major physiological disruption. Post-stroke depression occurs in approximately 27–33% of stroke survivors, a rate confirmed across numerous meta-analyses and recognized in a formal scientific statement from the American Heart Association and American Stroke Association, which notes that affected patients face higher mortality and worse functional recovery. Depression following cardiac surgery affects between 23 and 61% of patients. Cancer-related depression occurs in roughly 16–25% of patients across tumor types. Depression is documented in approximately 20% of patients with chronic kidney disease, heart failure, and those on long-term dialysis. None of these conditions are attributed to laziness or weak character — they are treated as medical sequelae of physiological stress, recognized by every major clinical body, and managed accordingly. The analytical framework applied to depression after stroke or cardiac surgery must, for the sake of internal consistency, apply equally to depression after childbirth.
Social factors matter — but they are not the whole story, and they do not replace the biological one. Cross-national prevalence data, the specific neurobiological pathways now identified in PPD, the response to mechanism-targeted pharmacotherapy, and the occurrence of PPD in women with excellent social support and planned pregnancies all converge on the same conclusion. The most accurate model is biopsychosocial: a biological vulnerability, triggered by specific hormonal and neurosteroid changes, amplified or buffered by social, relational, and material context. The claim that postpartum depression is a modern invention, a form of laziness, or merely an excuse for avoiding responsibilities is not supported by current historical, clinical, biological, or epidemiological evidence. It is a claim that, on examination, has no scientific foundation — and one that, when acted upon, causes real and avoidable harm to mothers, infants, and families.
